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Background: Dementia is a prevalent neurodegenerative disorder affecting an estimated 24.3 million people across
the globe. The burden on those caring for people with dementia is substantial, with widespread implications for
the caregiver, the care recipient and the community. Relaxation techniques, such as Transcendental Meditation®
(TM), have been shown to reduce stress and anxiety in healthy workers; similar benefits are anticipated in dementia
caregivers. The objective of this study was to ascertain whether TM can improve psychological stress, quality of life,
affect and cognitive performance in dementia caregivers.
Methods: The study was conducted as a pilot prospective, multi-centre, community-based, randomised wait-list
controlled trial. Community-dwelling caregivers of persons with diagnosed dementia were randomly assigned to a
12-week (14-hour) TM training program or wait-list control. Participants were assessed for quality of life, stress, affect,
cognitive performance and adverse effects. The feasibility of the study was also evaluated.
Results: Seventeen caregivers were recruited and randomised. Improvements in WebNeuro response speed scores
over time were significantly (p = 0.03) greater in the TM group relative to control. Changes between groups over
time in all other primary and secondary outcome measures did not reach statistical significance. However, there
was a trend toward greater improvement in WebNeuro stress, depression and negativity bias scores in the TM
group. Adverse events were reported amongst 63 % of TM-treated subjects; however, events were generally
transient, of mild-moderate intensity and only ‘possibly’ related to TM.
Conclusions: Dementia caregivers exposed to TM demonstrated varying degrees of improvement in several
measures of cognitive function, mood, quality of life and stress following exposure to TM. However, as the pilot
study was underpowered, no firm conclusions can be made about the effectiveness of TM in this caregiver
population. Findings from full-scale trials are now warranted.
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Dementia (recently re-termed neurocognitive disorder)
[1] is a syndrome characterised by progressive decline in
global cognitive ability and increasing dependence on
others (such as family) for completion of instrumental
activities of daily living. It is estimated that more than
24.3 million people across the globe suffer from the dis-
order; predicted to rise to over 81.1 million by 2040 [2].
In Australia, 266,000 people have dementia [3], which
accounts for 5.3 % of all disability-adjusted life years lost
due to disease in older Australians [4]. The combination
of chronicity and prevalence contributes to a substantial
disease burden, with the total financial cost of dementia
care in Australia in 2011 predicted to be close to
AU$10.8 billion (US$11.5 billion).
The disease burden for relatives of dementia sufferers
can be significant, with associated stress in particular be-
ing consistently identified as a key source of financial
hardship in family caregivers (i.e. from reduced working
hours or relinquished employment) [5], as well as phys-
ical and psychological morbidity, including sleep disturb-
ance, depression, anxiety, social isolation, comorbid
illness, impaired cognitive performance, and reduced
quality of life [6–9]. Whilst stress-management pro-
grams for this group are prevalent, they often involve
substantial ongoing time-investment and re-training
from time-poor individuals; consequently, such pro-
grams are subject to poor retention rates and modest
overall effectiveness [10].
A sustainable alternative to stress-management in this
target group, which is potentially low-cost, relatively ef-
fortless, easily implemented and convenient (i.e. can be
practiced anywhere and anytime), is Transcendental
Meditation® (TM) [11]. This highly-standardised, auto-
matic self-transcending form of meditation allows an in-
dividual’s attention to drift to a less active, quieter style
of mental functioning, to yield a unique psychophysio-
logical state of restful alertness [11]. This is in contrast
to other forms of meditation, such as the focussed atten-
tion techniques (e.g. Tibetan Buddhism, Qigong) and
open monitoring techniques (e.g. mindfulness, Sahaja
yoga), which are generally more contemplative/concen-
trative in nature, effortful, and focussed on the present
moment [12].
Evidence from several randomised controlled trials
(RCTs) has already shown TM to be effective at improv-
ing a number of psycho-behavioural outcomes, including
psychological stress, distress, anxiety, depression, quality
of life, emotional and social wellbeing, and mental health
[13–16]. However, there are no known studies that have
examined the effects of TM on any outcome in care-
givers. Findings from a small US pilot study of 31 demen-
tia caregivers suggest that another form of relaxation
therapy, mindfulness meditation, may be more effectivethan respite in reducing caregiver stress [17]. In view of
these findings, and the results of an earlier RCT showing
TM to be comparable with other kinds of relaxation ther-
apies in reducing anxiety in patients diagnosed with anx-
iety neurosis [18], it is plausible that TM also may be
beneficial in attenuating stress and anxiety in caregivers of
persons with dementia.
Given the implications of stress on caregivers, their
family and the wider community, and the favourable ef-
fects of TM on stressful symptoms; while bearing in
mind the absence of data on the effects of TM in care-
givers, further research in this area is justified. Utilising
a randomised, wait-list controlled trial design, the aims
of the current study were to (1) determine the effective-
ness of a TM-based training program on psychological
stress, quality of life, affect and a range of key cognitive
function indices in community-dwelling caregivers of de-
mentia sufferers, and (2) assess the feasibility of con-
ducting a full-scale trial in this area.
Methods
Study design
The Transcendental Meditation for caregivers of demen-
tia sufferers trial (TRANSCENDENT) was a pilot pro-
spective, multi-centre, randomised wait-list controlled
trial (RCT) with two parallel arms. A detailed descrip-
tion of the study protocol is reported elsewhere [19].
Objectives
The project was designed to address the following
objectives.
Primary objectives
1. Establish whether TM improves health-related quality
of life in community-dwelling caregivers of dementia
sufferers when compared to wait-list control (WLC).
2. Ascertain whether TM reduces psychological stress in
community-dwelling caregivers of dementia sufferers
when compared to WLC.
Secondary objectives
1. Determine whether TM improves affect in
community-dwelling caregivers of dementia sufferers
relative to WLC.
2. Ascertain whether TM improves cognitive
performance in community-dwelling caregivers of
dementia sufferers when compared to WLC.
3. Determine whether TM is cost-effective in improving
health-related quality of life in community-dwelling
caregivers of dementia sufferers relative to WLC.
4. Establish whether TM is associated with a greater
incidence and/or severity of adverse events in
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relative to WLC.
5. Ascertain the feasibility of implementing the project
as a larger RCT.
Participants
Individual caregivers were eligible to participate in TRAN-
SCENDENT if they were non-professional, community-
dwelling caregivers of a person with diagnosed dementia;
had not received previous instruction on the TM tech-
nique; were able to provide written consent; were able to
speak, read and understand the English language, and
were available and willing to complete all follow-up assess-
ments and intervention sessions. Participants were ex-
cluded if they had a history of any medical condition
causing moderate to severe cognitive impairment; had
commenced or ceased psychotropic medication within the
past six weeks; had participated in a clinical trial within
the past thirty days, where psychological outcomes and
quality of life were outcomes of interest; had practiced
some form of mind-body therapy on a regular basis (i.e. at
least once a month); consulted a psychologist/psychiatrist
at least once a week, and had taken a recreational drug fif-
teen days prior to enrolling in the study.
The estimated size of the study population was based
on an expected mean difference in quality of life (i.e.
AQoL-8D utility index) of 0.1 utility points between the
TM and wait-list control groups. Assuming a standard
deviation of 12.5 % and 10 % attrition, a sample size of
18 patients was required in each arm. A total of 36 par-
ticipants would provide 80 % power for a two-way re-
peated measures analysis of variance (RM-ANOVA) to
detect a statistically significant difference in quality of
life with a two-tailed alpha level set at 0.05.
Setting
The project was administered by the University of South
Australia, and implemented through The Positive Ageing
Centre (Woodside, South Australia), and the Maharishi
Invincibility Centre (Parkside, South Australia).
Recruitment
Participant recruitment commenced in April 2013 and
was completed by March 2014. A range of promotional
strategies, forming part of a comprehensive recruitment
campaign, were employed across multiple settings. A de-
tailed description of the TRANSCENDENT recruitment
campaign, including the recruitment yield of each strat-
egy, will be reported in a separate publication. In brief,
the strategies included the distribution of study flyers
across multiple settings (i.e. University of South
Australia, Adelaide Hills Council, general practice sur-
geries, South Australian caregiver respite agencies); the
posting of regular notices about the trial on Twitter,Facebook and pertinent organisation websites; the imple-
mentation of a four-week Google Adwords campaign;
the publication of study information in a state-wide peri-
odical for senior citizens (i.e. The Senior), a national on-
line resource on residential aged care (i.e. the DPS
guide) and four association newsletters/reports; a news-
paper display advertisement; the presentation of short
seminars on stress management for caregivers attending
three large South Australian caregiver respite agencies,
and the broadcasting of three local radio station interviews,
a state television news story and five newspaper stories.
Caregivers expressing interest to participate in the pro-
ject were asked to contact the research assistant (by
phone) for further information and screening. Those eli-
gible to participate in the study were subsequently sent a
copy of the participant information sheet and consent
form to read and discuss with family or friends in order
to make an informed decision about their involvement.
One-week after dispatching the study information, par-
ticipants were contacted by phone and their ‘capacity to
give consent’ (i.e. the ability to provide a brief description
of the study purpose, and outline what their involvement
in the study entailed) was gauged. Participants who were
able to provide a satisfactory response to these questions
were invited to sign the written consent form and return it
to the research assistant using the attached reply-paid
envelope.
Randomisation
Enrolled participants were randomly assigned to Tran-
scendental Meditation® or wait-list control at a ratio of
1:1. To approximate equality of sample sizes in each
study group, block randomisation was performed with
computer-generated randomly permuted blocks of four
by a researcher not involved in the treatment assignment
process. Randomisation codes were held in sequentially
numbered opaque sealed envelopes and each were se-
lected by the research assistant (who was unaware of the
allocation sequence) in consecutive order at the time of
participant enrolment.
Outcomes
The primary outcomes of TRANSCENDENT were
Health-related quality of life (HR-QoL) and stress. HR-
QoL index scores were measured using the paper-based,
self-administered, 35-item Assessment of Quality of Life
8-dimension (AQoL-8D) instrument. Stress was mea-
sured using the WebNeuro test battery; this internet-
based, self-administered, neurocognitive assessment tool
has demonstrated excellent convergent validity in
healthy young to middle-aged adults [20], and has been
used in a number of studies looking at changes in cogni-
tive function in obese [21] and diabetic populations [22],
and children with disruptive behaviours [23].
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ure the secondary outcomes of affect (i.e. emotional resili-
ence, feelings of depression and feelings of anxiety) and
cognitive performance (including psychomotor response
speed, impulsivity, attention and concentration, informa-
tion processing efficiency, working memory and executive
function). Adverse events (including description, severity
and duration of symptom, probability of symptom being
related to study intervention, and action taken) were mea-
sured using a standardised adverse event record, which
was self-administered by participants throughout the
intervention phase of the study. Cost-effectiveness was de-
termined using cost-utility analysis, which examined the
cost and effectiveness of each intervention using the
quality-adjusted life year (QALY) as its unit of effective-
ness (using the AQoL-8D to derive quality of life utility
scores). If a statistically significant change in quality of life
was detected between groups, then the cost of each inter-
vention (as derived from trial cost data) was combined
with QALYs to estimate cost per QALY gain. The final
secondary outcome, feasibility, served to evaluate the ease
and practicality of reproducing the study on a larger scale;
the feasibility of the trial will be reported in a separate
publication. Excluding feasibility and cost-effectiveness, all
outcomes were assessed at baseline (week 0), post-
intervention (week 12) and follow-up (week 24), and all
assessments preceded intervention exposure.
Interventions
Participants were randomly assigned to one of two
groups: (a) a 12-week (14-hour) TM training program
plus 12-week follow-up, delivered face-to-face by an ex-
perienced TM instructor, or (b) a 24-week wait-list con-
trol. A detailed description of the intervention and
control is reported elsewhere [19].
Statistical analysis
Data from all completed outcome measures were entered
into SPSS (v.21), and analysed by intention-to-treat. Mea-
sures of central tendency and variability were used for de-
scriptive data where values were normally distributed.
Medians and the interquartile range were used to describe
data that was not normally distributed. For categorical var-
iables, frequency distributions and percentages were used
to describe categorical data. The t-test for independent
groups was used to examine differences between groups at
baseline. Outcome differences between groups, differences
over time and any differential treatment effect at different
points in time were examined using RM-ANOVA.
Ethics
Human ethics approval was granted by the Human Re-
search Ethics Committee of the University of South
Australia.Results
From April 2013 to March 2014, 40 individuals were
screened, of which 17 were eligible for inclusion in the
study (Fig. 1). The reason for exclusion in 52 % (12/23)
of excepted cases was an inability to commit to the
intervention schedule; this was followed by 35 % (8/23)
of excluded cases not meeting the inclusion criteria. All
17 participants included in the study were randomised,
with 8 assigned to TM and nine assigned to wait-list
control. One participant (12.5 %) in the TM group with-
drew at week 23 due to the death of a spouse; there were
no withdrawals in the control group.
Baseline demographics
The majority of participants were female (88 %), elderly
(mean age: 66.12 ± 8.50 years), married to the dementia
sufferer (64.7 %), provided full-time care (121.63 ±
68.04 h/week) for the person with dementia, and had
been providing care for a mean duration of 5.57 ±
3.58 years. Caregivers also demonstrated a moderate de-
gree of depression (mean WebNeuro depression score:
5.05 ± 2.10), anxiety (mean WebNeuro anxiety score:
5.12 ± 2.49), stress (mean WebNeuro stress score: 4.27 ±
1.78), and low quality of life (mean AQoL-8D utility
score: 0.66 ± 0.18). None of the caregivers smoked ciga-
rettes, and mean weekly alcohol consumption was low
(4.09 ± 4.48). There were no statistically significant dif-
ferences between groups at baseline for any demo-
graphic variable or outcome measure (Table 1).
Quality of life
A marginally significant increase in AQoL-8D utility
scores was observed within groups over time (F (2,30) =
3.099, p = 0.060, η2 = 0.171). Whilst a trend toward
greater improvement in AQoL-8D utility scores was ob-
served in the TM group relative to the control group at
week 12 (Fig. 2), differences in utility scores between
groups were not statistically significant over time (F
(1,15) = 0.025, p = 0.878, η2 = 0.002). Consequently, a
cost-utility analysis was not performed.
Differences within groups were marginally significant
for the AQOL-8D domains of mental health (F (2,30) =
3.125, p = 0.059, η2 = 0.172) and pain (F (2,30) = 3.284, p =
0.051, η2 = 0.180), and statistically significant for the phys-
ical health superdomain (F (2,30) = 3.511, p = 0.043, η2 =
0.190). There were also statistically significant differences
between groups at week 12 for the domains of happiness
(MD = 0.10, SD = 0.10, p = 0.001) and coping (MD= 0.09,
SD = 0.15, p = 0.034), and for the mental superdomain
(MD= 0.09, SD = 0.14, p = 0.024) (Table 2). There were no
statistically significant differences between groups over
time for any of the AQoL-8D domains, including inde-
pendent living (F (1,15) = 0.381, p = 0.546, η2 = 0.025), hap-
piness (F (1,15) = 0.245, p = 0.628, η2 = 0.016), mental
Fig. 1 Participant flow chart
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(1,15) = 1.219, p = 0.287, η2 = 0.075), relationships (F
(1,15) = 0.485, p = 0.497, η2 = 0.031), self-worth (F (1,15) =
0.550, p = 0.470, η2 = 0.035), pain (F (1,15) = 0.008, p =
0.928, η2 = 0.001) and senses (F (1,15) = 0.818, p = 0.380,
η2 = 0.052), or for the mental health (F (1,15) = 0.897, p =
0.359, η2 = 0.056) and physical health superdomains (F
(1,15) = 0.190, p = 0.669, η2 = 0.013).
Stress
A significant improvement in WebNeuro stress scores
was observed within groups over time (F (2,30) = 5.961,
p = 0.007, η2 = 0.284). Changes in stress scores between
groups were not statistically significant (F (1,15) = 1.350,
p = 0.263, η2 = 0.083); however, there was a non-
significant trend toward greater improvement in those
who received TM (Fig. 3).
Affect
Whilst the TM group demonstrated a noticeable trend
toward greater improvement in WebNeuro depression
scores over time (Fig. 4), the difference in depression
scores within groups (F (2,30) = 0.936, p = 0.403, η2 =
0.059) and between groups (F (1,15) = 0.034, p = 0.856,
η2 = 0.002) did not reach statistical significance. Al-
though a marginally significant improvement in anxiety
scores was observed in the control group at week 12when compared to the TM group (MD = -1.10, SD =
2.07, p = 0.046) (Table 3), there was no statistically sig-
nificant difference within groups (F (2,30) = 1.314, p =
0.284, η2 = 0.081) or between groups (F (1,15) = <0.001,
p = 0.998, η2 = <0.001) in WebNeuro anxiety scores over
time.
Cognitive function
WebNeuro response speed score
There was no significant improvement in WebNeuro re-
sponse speed scores within-groups over time (F (2,26) =
1.125, p = 0.340, η2 = 0.080). Changes in scores between
groups over time were statistically significant, in favour
of TM (F (1,13) = 5.774, p = 0.032, η2 = 0.308) (Fig. 5).
A marginally significant improvement in WebNeuro
negativity bias scores was observed within-groups over time
(F (2,30) = 3.20, p = 0.055, η2 = 0.176). Changes in scores be-
tween groups were not statistically significant (F (1,15) =
1.499, p = 0.240, η2 = 0.091). However, a noticeable trend
toward greater improvement was observed in the TM
group (Fig. 6). There were no statistically significant
changes between-groups over time in WebNeuro emo-
tional resilience (F (1,15) = 0.200, p = 0.661, η2 = 0.013),
social skills (F (1,15) = 1.644, p = 0.219, η2 = 0.099), impul-
sivity (F (1,13) = 2.771, p = 0.120, η2 = 0.176), attention and
concentration (F (1,14) = 0.008, p = 0.930, η2 = 0.001), infor-
mation processing (F (1,15) = 2.481, p = 0.136, η2 = 0.142),
Table 1 Baseline characteristics of participants
TM group WLC P value
(n = 8) (n = 9)
Age [years], mean (SD) 69.4 (7.3) 63.2 (8.8) 0.141
Sex, n (%) Female 7 (87.5 %) 8 (88.9 %) 0.735
Male 1 (12.5 %) 1 (11.1 %)
Total 8 (100 %) 9 (100 %)
Number of standard alcoholic drinks consumed
per week, mean (SD)
4.06 (4.63) 4.13 (4.64) 0.979
Number of cigarettes smoked per day, mean (SD) 0 (0 %) 0 (0 %) -
Relationship to person with dementia, n (%) Daughter/son 3 (37.5 %) 3 (33.3 %) 0.627
Wife/Husband 5 (60.0 %) 6 (66.7 %)
Total 8 (100 %) 9 (100 %)
Duration of dementia caregiving role [years], mean (SD) 6.75 (3.57) 4.21 (3.32) 0.179
Intensity of dementia caregiving role [hours/week],
mean (SD)
118.06 (68.93) 125.71 (72.27) 0.837
AQoL-8D, mean (SD) Utility score 0.65 (0.23) 0.66 (0.14) 0.877
Independent living domain score 0.87 (0.13) 0.90 (0.11) 0.719
Happiness domain score 0.72 (0.14) 0.76 (0.08) 0.556
Mental health domain score 0.56 (0.12) 0.52 (0.08) 0.449
Coping domain score 0.78 (0.14) 0.74 (0.13) 0.568
Relationships domain score 0.69 (0.21) 0.63 (0.12) 0.498
Self-worth domain score 0.77 (0.18) 0.84 (0.09) 0.381
Pain domain score 0.75 (0.30) 0.76 (0.18) 0.941
Senses domain score 0.82 (0.18) 0.91 (0.11) 0.207
WebNeuro scores, mean (SD) Stress 4.50 (2.05) 4.06 (1.59) 0.629
Depression 5.13 (2.33) 5.00 (2.02) 0.908
Anxiety 5.44 (2.31) 4.83 (2.75) 0.630
Negativity bias 2.63 (2.74) 2.11 (1.32) 0.639
Emotional resilience 5.81 (1.81) 5.50 (2.82) 0.787
Social skills 6.94 (1.24) 5.72 (2.49) 0.219
Response speed 4.07 (2.54) 6.88 (2.84) 0.065
Impulsivity 4.29 (2.69) 5.94 (2.99) 0.281
Attention & concentration 4.50 (2.04) 3.17 (2.54) 0.264
Information processing efficiency 3.13 (2.28) 3.89 (2.06) 0.482
Memory 4.29 (1.72) 4.67 (1.87) 0.680
Executive function 4.42 (3.26) 5.11 (2.52) 0.670
Emotion identification 4.07 (2.20) 3.44 (1.21) 0.495
Emotion bias 4.63 (2.68) 4.00 (1.99) 0.598
AQoL-8D assessment of quality of life (8-dimension) instrument, SD standard deviation, TM Transcendental Meditation®, WLC wait-list control.
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function (F (1,13) = 0.027, p = 0.871, η2 = 0.002), emotion
identification (F (1,15) = 0.090, p = 0.768, η2 = 0.006) and
emotion bias scores (F (1,15) = 0.026, p = 0.874, η2 = 0.002).
Adverse events
No participants in the control group reported an adverse
event. Five participants in the TM group reported a totalof eight adverse events. In 7 (88 %) cases, adverse events
were short-lived (≤3 h duration). Adverse events were of
moderate intensity in five (67 %) cases, mild intensity in
one (13 %) case, and severe (i.e. sciatica) in one (13 %)
case. In all reports, participants believed the event ‘pos-
sibly’ related to TM. Events were primarily neurological
in nature, with one report each of headache, neck and






























Fig. 2 Mean Aqol-8D utility scores by treatment group at baseline,


























Fig. 3 Mean WebNeuro stress scores by treatment group at baseline,
week 12 and week 24
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tated referral to a health professional, with 4 (50 %)
cases requiring conservative action only (e.g. change of
position, distraction, relaxation), 3 (38 %) cases requiring
no action, and one case (13 %) necessitating single ad-
ministration of a mild analgesic.
Discussion
This is the first known randomised controlled trial to
examine the safety and effectiveness of TM for psycho-
logical stress, quality of life, affect and cognitive per-
formance in dementia caregivers. The findings of this
trial suggest that a 12-week TM training program offers
little benefit over wait-list control for most outcomes; al-
though, there are some areas where TM shows promise.
Caregivers of dementia sufferers demonstrate poorer
quality of life relative to the general population [24–26].Table 2 Changes in mean AQoL-8D scores by group at weeks 0, 12
AQoL-8D score TM group (n = 8)
Baseline Week 12 Week 24
Utility score 0.65 (0.23) 0.74 (0.21) 0.70 (0.21)
Independent living domain score 0.87 (0.13) 0.87 (0.15) 0.88 (0.12)
Happiness domain score 0.72 (0.14) 0.81 (0.11) 0.77 (0.12)
Mental health domain score 0.56 (0.12) 0.61 (0.13) 0.58 (0.12)
Coping domain score 0.78 (0.14) 0.85 (0.08) 0.78 (0.13)
Relationships domain score 0.69 (0.21) 0.69 (0.24) 0.69 (0.22)
Self-worth domain score 0.77 (0.18) 0.81 (0.16) 0.81 (0.15)
Pain domain score 0.75 (0.30) 0.84 (0.27) 0.80 (0.29)
Senses domain score 0.82 (0.18) 0.90 (0.09) 0.90 (0.07)
Mental superdomain 0.35 (0.21) 0.42 (0.22) 0.37 (0.22)
Physical superdomain 0.66 (0.24) 0.77 (0.23) 0.74 (0.21)
AQoL-8D assessment of quality of life (8-dimension) instrument, SD standard deviat
*Statistically significant at p < 0.05.
aControlling for baseline values.This study substantiates these findings, with the mean
AQoL-8D (quality of life) index score for caregivers at
baseline shown to be 21 % lower than AQoL-8D popula-
tion norms for Australians aged ≥65 years (i.e. 0.66 vs.
0.84) [26]. Lower quality of life was evident amongst
caregivers relative to population norms across all AQoL-
8D domains except for independent living and senses.
Despite the poor quality of life of dementia caregivers,
and the significant differences between groups in several
AQoL-8D domain scores (i.e. happiness, coping, mental
superdomain) at twelve weeks (in favour of TM), TM
did not significantly improve AQoL-8D utility or domain
scores over time when compared with wait-list control.
This is not consistent with the findings of other rando-
mised controlled trials, which have shown TM to signifi-
cantly improve the quality of life of adults with breast
cancer [16], congestive heart failure [27] and HIV [28].and 24 (mean, SD)










Baseline Week 12 Week 24
0.66 (0.14) 0.67 (0.10) 0.71 (0.12) 0.08 (0.19) −0.002 (0.17)
0.90 (0.11) 0.91 (0.08) 0.91 (0.08) −0.03 (0.22) −0.01 (0.12)
0.76 (0.08) 0.73 (0.07) 0.74 (0.09) 0.10 (0.10)* 0.05 (0.15)
0.52 (0.08) 0.54 (0.05) 0.57 (0.06) 0.04 (0.12) −0.02 (0.12)
0.74 (0.13) 0.74 (0.12) 0.76 (0.10) 0.09 (0.15)* −0.001 (0.17)
0.63 (0.12) 0.61 (0.08) 0.66 (0.11) 0.03 (0.17) −0.02 (0.17)
0.84 (0.09) 0.84 (0.08) 0.84 (0.11) 0.01 (0.16) 0.02 (0.17)
0.76 (0.18) 0.82 (0.13) 0.84 (0.14) 0.02 (0.23) −0.03 (0.29)
0.91 (0.11) 0.89 (0.11) 0.92 (0.08) 0.02 (0.22) 0.006 (0.13)
0.30 (0.11) 0.29 (0.07) 0.33 (0.10) 0.09 (0.14)* 0.004 (0.14)
0.73 (0.17) 0.76 (0.15) 0.79 (0.14) 0.05 (0.27) −0.006 (0.22)





























Fig. 4 Mean WebNeuro depression scores by treatment group at
































Fig. 5 Mean WebNeuro response speed scores by treatment group
at baseline, week 12 and week 24
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the small sample size of the current study, two of the
aforementioned trials were also small studies [27,28],
with sample sizes of less than 24 participants. Duplica-
tion of the current study with a much larger sample size,
together with the use of additional measures of quality
of life (including caregiver-specific measures such as
ProQolid), should further our understanding of the ef-
fects of TM on the quality of life of dementia caregivers.
The considerable level of psychological stress reported
by dementia caregivers in the current study corroborates
the findings of earlier reports [29,30], drawing attention
to the negative effects of caring for a person with de-
mentia [31]. The current study demonstrated that both
TM and wait-list control significantly improved stressTable 3 Changes in mean WebNeuro scores by group at weeks 0, 1
WebNeuro scores TM group (n = 8) W
Baseline Week 12 Week 24 Ba
Stress 4.50 (2.05) 5.68 (1.60) 5.87 (1.98) 4.
Depression 5.13 (2.33) 5.38 (2.08) 5.81 (1.81) 5.
Anxiety 5.44 (2.31) 5.44 (2.21) 5.69 (1.98) 4.
Negativity bias 2.63 (2.74) 3.63 (3.02) 3.81 (2.52) 2.
Emotional resilience 5.81 (1.81) 5.88 (2.00) 5.81 (2.93) 5.
Social skills 6.94 (1.24) 6.75 (2.58) 6.56 (2.43) 5.
Response speed 4.07 (2.54) 3.81 (2.89) 5.00 (2.80) 6.
Impulsivity 4.29 (2.69) 4.21 (2.86) 4.57 (2.49) 5.
Attention & concentration 4.50 (2.04) 2.36 (1.97) 3.86 (2.14) 3.
Information processing efficiency 3.13 (2.28) 3.25 (2.65) 3.88 (2.08) 3.
Memory 4.29 (1.72) 4.13 (2.83) 3.25 (2.16) 4.
Executive function 4.42 (3.26) 5.75 (3.05) 4.38 (2.72) 5.
Emotion identification 4.07 (2.20) 4.50 (1.95) 4.94 (1.45) 3.
Emotion bias 4.63 (2.68) 4.69 (2.32) 5.00 (1.75) 4.
TM Transcendental Meditation®, WLC wait-list control.
*Statistically significant at p < 0.05.
aControlling for baseline values.scores in dementia caregivers over time; this points to-
ward the possible influence of contextual factors. Time-
out from the caregiving role (i.e. respite) to complete the
study assessments and the opportunity to speak to fellow
caregivers post-assessment - both of which may alleviate
caregiver burden [32]–may have contributed to improve-
ments in stress scores in both groups. Notwithstanding,
there was some indication that caregivers in the TM
group experienced a greater degree of improvement in
stress levels, suggesting a possible intervention effect.
Whilst the positive effects of TM on stress are well-
documented [14,33,34], the statistical and clinical signifi-
cance of these effects needs to be substantiated by data
from larger trials. Based on the findings of the current
study, we calculate that a total sample size of 60 would2 and 24 (mean, SD)






seline Week 12 Week 24
06 (1.59) 4.61 (1.22) 5.06 (1.18) 0.82 (1.93) 0.63 (2.92)
00 (2.02) 5.44 (1.36) 5.44 (1.45) −0.13 (2.82) 0.31 (2.73)
83 (2.75) 6.17 (1.46) 5.56 (2.08) −1.10 (2.07)* −0.12 (3.16)
11 (1.32) 2.17 (1.20) 2.22 (1.23) 0.97 (2.06) 1.19 (2.22)*
50 (2.82) 5.50 (2.39) 5.17 (2.14) 0.17 (3.28) 0.51 (4.82)
72 (2.49) 5.89 (2.09) 5.11 (1.50) −0.12 (3.64) 0.80 (3.64)
88 (2.84) 6.63 (2.88) 6.94 (2.48) −0.45 (5.46) −2.26 (5.36)
94 (2.99) 6.67 (2.54) 6.83 (2.37) −1.18 (4.95) −1.41 (4.93)
17 (2.54) 3.50 (2.86) 4.33 (2.50) −2.18 (4.12)* −1.28 (4.23)
89 (2.06) 5.61 (2.32) 5.06 (2.48) −2.01 (4.79) −1.04 (4.79)
67 (1.87) 4.83 (2.33) 4.61 (2.73) −1.17 (3.51) −1.62 (4.13)
11 (2.52) 4.94 (2.31) 5.61 (2.26) 1.51 (4.02) −0.50 (3.73)
44 (1.21) 4.61 (3.38) 4.67 (2.02) −0.66 (4.92) −0.06 (3.20)































Fig. 6 Mean WebNeuro negativity bias scores by treatment group at
baseline, week 12 and week 24
Leach et al. BMC Complementary and Alternative Medicine  (2015) 15:145 Page 9 of 11be required to detect a mean difference in WebNeuro
stress score of 0.8 between the TM and wait-list control
groups (assuming a standard deviation of 1.6, 10 % attri-
tion, a two-tailed alpha level of 0.01, and 90 % power for
a two-way repeated measures analysis of variance).
The current study failed to detect a significant differ-
ence in anxiety and depression scores between the TM
group and wait-list control group post-treatment. This
was an unexpected finding as high-level evidence sup-
ports the effectiveness of TM for anxiety [11,35], and to
a lesser extent, depression [32]. Given that there was a
trend toward greater improvement in depression scores
in the TM group, it is likely that the study sample was
not large enough to detect a significant difference be-
tween groups. It is also conceivable that the WebNeuro
test battery was not sufficiently sensitive to detect subtle
changes in affect amongst caregivers [20]. Thus, the util-
isation of more sensitive measures of affect should be
given due consideration in future studies.
There is some indication that TM may impact posi-
tively on several aspects of cognitive function in demen-
tia caregivers. Principally, TM significantly improved
response speed scores (as measured by the motor tap-
ping test) when compared with wait-list control. Im-
provements in response speed are indicative of increased
psychomotor speed, attention and coordination, and
may be a sign of improved affect [36]. This, together
with a trend toward greater improvement in negativity
bias scores (i.e. the tendency to see oneself and the
world as negative), coincides with the non-significant
improvement in depression scores observed in partici-
pants receiving TM. Given the number of indicators
pointing toward an improved affect in dementia care-
givers exposed to TM, there is clear justification to ex-
plore this relationship further.
A number of reviews of TM have drawn attention to
the absence or poor reporting of adverse events in TM
trials to date [35,37]. Accordingly, this is possibly theonly known trial to report in sufficient detail the safety
of TM. Adverse events reported by participants exposed
to TM were generally transient, easily managed and of
mild to moderate intensity; the events were also only
weakly related to the intervention. The nature of the
symptoms, which were primarily neurological, suggest
that the effects were probably attributed to prolonged
sitting rather than to TM per se, with prolonged sitting
known to exacerbate sciatica, paraesthesia and arthralgia
[38]; further, a change of position alleviated these symp-
toms in some cases. Another explanation is that TM in-
creased participant self-awareness, resulting in greater
attention given to pre-existing conditions; although, this
has yet to be substantiated. Improved reporting of ad-
verse events in future trials of TM will provide add-
itional insight into the safety of this therapy.
There are some limits to the conclusions that can be
drawn from this study. Firstly, despite the implementa-
tion of a comprehensive 12-month recruitment cam-
paign, the required sample size could not be reached,
and as a result, the study was underpowered; hence, it is
likely that for most study outcomes, the absence of any
significant difference between groups may have been the
product of a type 2 error (i.e. false negative result)
[39,40]. Similarly, where statistically significant differ-
ences were detected between groups, the possibility of a
type 1 error (i.e. false positive result) cannot be excluded
[39,40]. These limitations must be considered alongside
the strengths of the study, including the robust rando-
mised controlled trial design, the use of valid and reli-
able outcome measures, the homogeneity of the sample,
the high-retention rate, and the medium-term (i.e. six-
month) duration of the trial.
Given the limitations of the study, it would be prema-
ture to propose any recommendations for clinical prac-
tice. However, the experiences gained throughout this
pilot study make it possible to put forward several rec-
ommendations for future research. First, it is evident
that the study protocol is feasible to conduct as a larger
clinical trial, noting that there will need to be some
minor revisions; namely, the provision of respite for de-
mentia sufferers, assistance with transportation to and
from the study site, and greater flexibility with the
scheduling of appointments. Second, the inclusion of
caregiver-specific measures of quality of life and more
sensitive measures of depression and anxiety should be
given due consideration; although, the burden of these
additional assessments should be weighed against the pos-
sible impact on participant recruitment and retention.
Conclusions
The findings of this pilot study lend little support to the
use of TM for the improvement of psychological stress,
affect and cognitive performance in dementia caregivers.
Leach et al. BMC Complementary and Alternative Medicine  (2015) 15:145 Page 10 of 11However, the study does draw attention to a number of
areas where TM shows promise in this population; spe-
cifically, psychological stress, depression, negativity bias,
response speed and several quality of life domains. Repli-
cation studies, which take into account the recommen-
dations put forward by the authors, will enable firmer
conclusions to be drawn about the effectiveness of TM
in the dementia caregiver population.
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